ApicHope Pharmaceutical Group (300723.SZ): Injection Zaraponic acid concentrated solution obtains drug registration certificate.

ApicHope Pharmaceutical Group (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the concentrated solution of zoledronic acid for injection. The indication for the concentrated solution of zoledronic acid for injection is to be used in combination with standard antitumor drugs for the treatment of bone damage in patients with solid tumor bone metastases and multiple myeloma. It is also used to treat hypercalcemia (HCM) caused by malignant tumors. The main pharmacological action of zoledronic acid is to inhibit bone resorption. In in vitro experiments, zoledronic acid inhibits osteoclast activity and induces osteoclast apoptosis. By binding to bone, zoledronic acid also blocks the resorption of mineralized bone and cartilage. Zoledronic acid inhibits the increased osteoclast activity and bone calcium release caused by various stimulating factors released by tumors. It is necessary to reduce excessive bone resorption and maintain adequate fluid replacement for the control of hypercalcemia in malignant tumors. Clinical studies in HCM patients have shown that a single dose of this product can reduce serum calcium and phosphorus levels, increase urinary calcium and phosphorus excretion.